Abstract
e14540Background: Bcl-2 inhibition has been explored therapeutically in B-cell malignancies. Venetoclax’s activity, a novel Bcl-2 inhibitor, is limited in Mcl-1 over-expressing DLBCL. The MCL-1, an...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
